Aurinia (AUPH) investors got cold feet today, sending shares tumbling nearly 9%. The reason?
This morning, Aurinia (AUPH) presented at the Cantor 4th Annual Healthcare Conference in New York City, and provided a corporate overview of its clinical …
Aurinia potentially has the 1st treatment for lupus nephritis, says RBC Capital’s Douglas Miehm.
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) fell nearly 5% in after-hours trading Thursday after it notified the SEC and shareholders that it would be …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced today that its common stock has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective before market …
Following a third quarter print and clinical update from Aurinia Pharmaceuticals (NASDAQ:AUPH) on its pivotal study in lupus nephritis (LN), Canaccord analyst Neil …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) served its third quarter earnings on Tuesday, but to Canaccord analyst Neil Maruoka, what matters most is the update …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has enticing clinical potential that has caught the eyes of more than one bull who have sounded off on …
H.C.
Ed Arce lifts his price target on AUPH after recent R&D day widened doors to voclosporin’s opportunity.
